Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) announced that its proprietary Mueller iodine extraction process has achieved 99.8% purity iodine with overall recovery exceeding 90% in recent laboratory tests. The process, designed to recover high-purity iodine from oilfield brine, is a key component of Voyageur's strategy to establish a domestic iodine supply for the North American radiology contrast media market and to provide oil and gas producers with a new revenue stream from produced water.
The company has established a laboratory and fabrication site in Houston, Texas, where it has been testing the process using real Anadarko and Permian Basin produced water. Laboratory operations have validated the process under controlled conditions and produced clean brine suitable for disposal or reinjection, aligning with zero-liquid-discharge objectives. A mobile, field-capable pilot unit, sized to treat 80,000 liters per day, has been constructed and is scheduled to begin field testing in the coming weeks, with operations planned for September 2026. This transition from bench-scale to continuous field operation using unaltered oilfield brine is considered critical for commercial deployment.
Key laboratory achievements include continuous operation with real oilfield brine, generation of clean brine for integration into existing disposal or desalination infrastructure, and validation of process parameters for scale-up. The company has also completed a preliminary design basis for a 200 metric ton per year plant and conducted techno-economic and environmental assessments supporting a low operating cost and environmental profile.
Field testing will provide operational data under real-world conditions, supporting the design of modular, relocatable production units. Voyageur's modular concept envisions deploying multiple 200 tonne/yr field units at saltwater disposal sites, where iodine concentrate would be produced and transported to a central hub for final polishing, prilling, and packaging. Engineering work is progressing on polishing, prilling, and packaging systems, and future phases will advance through front-end loading stages to refine cost estimates and commercial deployment plans.
For oil and gas operators and midstream companies, produced brine represents an untapped resource: billions of barrels are handled and disposed of annually at significant cost, yet only a small fraction of the iodine they contain is recovered. Voyageur aims to be the first to change that equation, building what it believes will be the first economically profitable, field-proven iodine extraction process. This aligns with the broader industry trend toward brine valorization.
Voyageur's vertically integrated strategy is designed to improve supply-chain security, reduce reliance on imported raw materials, and lower operating costs for medical imaging contrast agents. Iodine is a critical raw material for iodinated contrast media. Brent Willis, President and CEO, stated, "Achieving 99.8% purity and greater than 90% recovery in laboratory testing using real oilfield brine provides meaningful technical validation as we prepare for field pilot operations. This work supports our broader strategy of building a secure, vertically integrated supply chain for radiology drugs."
The company plans to develop iodine production capacity of up to 1,000 tonnes per year to support its future iodine-based contrast pharmaceutical production. Willis added, "Our staged approach is designed to validate iodine recovery in the field, advance modular production, and ultimately support future iodine-based drug manufacturing. By developing the Mueller process alongside our Frances Creek barium project and planned manufacturing capabilities, Voyageur is working to position itself across key parts of the medical imaging contrast media value chain."
Voyageur Pharmaceuticals is a Canadian developer of pharmaceutical-grade barium and iodine contrast media. The company owns a 100% interest in the Frances Creek barium sulfate project and intends to become the first vertically integrated company in the radiology contrast media drug market, embodying the motto "From Earth to Bottle." Further updates are expected as field testing begins and data is collected.
